Skip to content

Author

A. Mahajan

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Real-world efficacy and safety of trastuzumab emtansine biosimilar (UJVIRA®) in early and metastatic HER2-positive breast cancer: a multicenter pooled retrospective analysis from India

Trastuzumab-emtansine (T-DM1), an antibody drug conjugate, is approved in the adjuvant (residual disease post-neoadjuvant chemotherapy) and metastatic settings for HER2-positive breast cancer. Real-world evidence on T-DM1 biosimilar from India remains sparse. During October 2021–July 2025, 101 cases treated with T-DM1...

A. Mahajan, S. Panda, Lalatendu Moharana et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.